Market Overview

Insmed Up Over 30% Following FDA Decision

Related INSM
Markets Rise; Macy's Lowers Comparable Sales Outlook
Benzinga's Volume Movers

Insmed (NASDAQ: INSM) shareholders are having a big day. Shares are up over 33 percent after the company announced that the FDA granted Arikayce breakthrough therapy designation.

Arikayce is designed to treat lung infections; more specifically, nontuberculous mycobacterial lung disease.

Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.

Shares were last trading at $16.65, a 33.57 percent gain.

Posted-In: News FDA

 

Related Articles (INSM)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional